CA Botana International recalled 470 tubes of Doctor D. Schwab Controlling Cream on October 10, 2025. The recall stems from CGMP deviations that pose a high hazard risk. Consumers should stop using the product and seek guidance from healthcare providers.
CGMP Deviations
Consumers and healthcare providers should stop using this product immediately. Contact CA BOTANA International, Inc. or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recalled product is Doctor D. Schwab Controlling Cream containing 2.7% Benzoyl Peroxide, packaged in 1 FL OZ (30 ML) tubes. It was distributed across California, Colorado, Florida, Puerto Rico, and Washington, and has a lot code of D54066 with an expiration date of May 31, 2027.
The recall was initiated due to CGMP deviations, indicating potential quality issues in the manufacturing process. While specific incident data is unavailable, the classification as a Class II recall suggests moderate risk to consumers.
No specific injuries or incidents have been reported in connection with this product. The nature of CGMP deviations raises concerns about product quality.
Consumers and healthcare providers should stop using the recalled cream immediately. For further guidance, contact CA Botana International, Inc. or a healthcare provider. A notification letter will be provided to consumers.
For more information, consumers can visit the FDA recall page at www.accessdata.fda.gov or contact CA Botana International, Inc.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.